Serum Levels of Interleukin-34 and RANKL As Multivariable Predictors of Bone Erosion Seen by Ultrasonography in Patients with Ankylosing Spondylitis

Overview

Journal Asian Biomed (Res Rev News)

Date 2023 Aug 8

PMID 37551285

Authors

Xianqian Huang

Yong Chen

Yong Peng

Minzhi Gan

Baoqing Geng

Mengya Zhu

Ying Ying

Affiliations

Soon will be listed here.

Abstract

Background: Ankylosing spondylitis (AS) is a chronic inflammatory arthritic disease, and sacroiliitis, enthesitis, and propensity for sacroiliac and spinal fusion are characteristic pathological features. Interleukin-34 (IL-34) plays a role in the induction and differentiation of osteoclasts. Other inflammatory factors are not directly involved in the induction and differentiation, but play an indirect role by modulating the level of receptor activator of nuclear factor-κB (RANKL) and other molecules during the process of inflammatory bone destruction in AS. However, to our knowledge, the relationship between enthesitis and bone erosion, and IL-34 and RANKL in AS has not yet been elucidated.

Objective: To determine the correlation between serum IL-34, RANKL, and disease severity including enthesitis and bone erosion in patients with AS and develop multivariable predictive model.

Methods: We conducted a cross-sectional study of 40 patients with AS, compared with 40 patients with osteoarthritis, and 40 healthy volunteers. Their serum levels of IL-34 and RANKL were measured using enzyme-linked immunosorbent assays (ELISAs). Enthesitis and bone erosion were assessed with real-time ultrasonography. Spearman rank correlation coefficients were determined to analyze the relationship between the variables. Multiple logistic regression was used to determine associations and receiver operating characteristic (ROC) curve analyses were conducted to determine the diagnostic performance of cytokine levels.

Results: In patients with AS, serum levels of IL-34 (878.9 ± 116.4 pg/mL) and RANKL (155.6 ± 13.8 pg/mL) were significantly ( < 0.01) higher than those in patients with osteoarthritis (626.6 ± 79.0 and 138.1 ± 15.3 pg/mL, respectively) or a healthy group (612.9 ± 61.1 and 104.9 ± 15.4 pg/mL, respectively). Serum levels of IL-34 were not significantly correlated with the levels of RANKL. In patients with AS, serum levels of IL-34 and RANKL adjusted for age and weight were significantly correlated with enthesitis (0.798, < 0.01; 0.347, < 0.05, respectively) and bone erosion (0.822, < 0.01; 0.368, < 0.05, respectively). The area under the ROC curve (AUC) for the serum levels of IL-34 was 0.995 between patients with AS and healthy individuals. When serum level of IL-34 was >697.1 pg/mL, the sensitivity (SE) was >99% and specificity (SP) was 95.0%. The AUC for IL-34 was 0.982 between patients with AS and patients with osteoarthritis. When serum IL-34 was >688.4 pg/mL, the SE was >99% and SP 85.0%. IL-34 correlation with the number of bone erosions of enthesis was = 0.795, < 0.01. The AUC for serum RANKL was 0.993 between patients with AS and healthy individuals. When serum RANKL was >126.2 pg/mL, the SE was 97.5% and SP 97.5%. The AUC for serum RANKL was 0.798 between patients with AS and patients with osteoarthritis. When serum RANKL was >149.3 pg/mL, the SE was 70% and SP was 80.0%.

Conclusions: In patients with AS, serum levels of IL-34 and RANKL may be useful indicators of enthesitis, especially for bone erosions. IL-34 is associated with AS-associated enthesis damage and is a potential biomarker for predicting subsequent progression in patients with AS.

References

Chen C, Chen H, Liao H, Liu C, Tsai C, Chou C . Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010; 29(10):1155-61. DOI: 10.1007/s10067-010-1543-y. View

Ward M, Deodhar A, Akl E, Lui A, Ermann J, Gensler L . American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2015; 68(2):282-98. PMC: 5123840. DOI: 10.1002/art.39298. View

Schmidt S, Lo S, Hollestein L . Research Techniques Made Simple: Sample Size Estimation and Power Calculation. J Invest Dermatol. 2018; 138(8):1678-1682. DOI: 10.1016/j.jid.2018.06.165. View

Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S, Kitazawa S . RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol. 2002; 117(3):283-92. DOI: 10.1007/s00418-001-0376-9. View

Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K . Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986; 29(8):1039-49. DOI: 10.1002/art.1780290816. View

Maksymowych W . Disease modification in ankylosing spondylitis. Nat Rev Rheumatol. 2010; 6(2):75-81. DOI: 10.1038/nrrheum.2009.258. View

van der Linden S, VALKENBURG H, Cats A . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-8. DOI: 10.1002/art.1780270401. View

Collins G, Reitsma J, Altman D, Moons K . Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015; 162(1):55-63. DOI: 10.7326/M14-0697. View

Zhang W, Doherty M, Leeb B, Alekseeva L, Arden N, Bijlsma J . EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis. 2008; 68(1):8-17. DOI: 10.1136/ard.2007.084772. View

10.

Zhang W, Doherty M, Peat G, Bierma-Zeinstra M, Arden N, Bresnihan B . EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2009; 69(3):483-9. DOI: 10.1136/ard.2009.113100. View

11.

Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E . Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320(5877):807-11. DOI: 10.1126/science.1154370. View

12.

Chen Z, Buki K, Vaaraniemi J, Gu G, Vaananen H . The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011; 6(4):e18689. PMC: 3072988. DOI: 10.1371/journal.pone.0018689. View

13.

Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, Hiyoshi M, Motoyoshi K . IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010; 17(12):1917-27. DOI: 10.1038/cdd.2010.60. View

14.

Tian Y, Shen H, Xia L, Lu J . Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J Interferon Cytokine Res. 2013; 33(7):398-401. PMC: 3708624. DOI: 10.1089/jir.2012.0122. View

15.

Moon S, Hong Y, Ju J, Kwok S, Park S, Min J . Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J Rheumatol. 2013; 40(11):1842-9. DOI: 10.3899/jrheum.130356. View

16.

Wei S, Nandi S, Chitu V, Yeung Y, Yu W, Huang M . Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010; 88(3):495-505. PMC: 2924605. DOI: 10.1189/jlb.1209822. View

17.

Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K . The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991; 34(5):505-14. DOI: 10.1002/art.1780340502. View

18.

Baudhuin M, Renault R, Charrier C, Riet A, Moreau A, Brion R . Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol. 2010; 221(1):77-86. DOI: 10.1002/path.2684. View

19.

Clavel G, Thiolat A, Boissier M . Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine. 2013; 80(5):449-53. DOI: 10.1016/j.jbspin.2013.04.014. View

20.

Mou Y, Zhang P, Li Q, Lin Z, Liao Z, Wei Q . Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes. Clin Rheumatol. 2015; 34(6):1085-9. DOI: 10.1007/s10067-015-2940-z. View